Placebo-Controlled, Randomized, Double-Blind Study of IncobotulinumtoxinA for Sialorrhea
Neurol 92:e1982-e1991, Jost, W.H.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
NEJM 380:1795-1803,1865, Ma, H.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
IV and mechanical thrombolysis for ischemic stroke secondary to cardiac myxoma
Neurol 93:975-977, Barghouthi, T., et al, 2019
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Outcomes of Surgery for Brainstem Cavernous Malformations
Stroke 50:2964-2966, Kearns, K.N.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
In-Hospital Outcomes of Transcarotid Artery Revascularization and Carotid Endarterectomy in the Society for Vascular Surgery Vascular Quality Initiative
J Vasc Surg DOI:10.1016/J.JVS.2018.11.029, Schermerhorn,M.L.,et al, 2019
Therapeutic-Induced Hypertension in Patients with Noncardioembolic Acute Stroke
Neurol 93:e1955-e1963, Bang,O.H.,et al, 2019
Neurol 93:975-977, Barghouthi, T.,et al, 2019
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
NEJM 381:2103-2113,2171, Kapur, J.,et al, 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Three-year Follow-up of Prospective Trial of Focused Ultrasound Thalamotomy for Essential Tremor
Neurol 93:e2284-e2293, Halpern, C.H.,et al, 2019
Automated ASPECTS in Acute Ischmeic Stroke: A Comparative Analysis with CT Perfusion
AJNR 40:2033-2038, Sundaram, V.K.,et al, 2019
Association of Transcarotid Artery Revascularization vs Transfemoral Carotid Artery Stenting with Stroke or Death Among Patients with Carotid Artery Stenosis
JAMA 322:2313-2322, Schermerhorn, M.L.,et al, 2019
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
NEJM 378:11-22,81, Nogueira, R.G.,et al, 2018
Nusinersen Versus Sham Control in Later-Onset Spinal Muscular Atrophy
NEJM 378:625-635, Mercuri, E.,et al, 2018
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
NEJM 378:708-718, Albers, G.W.,et al, 2018
Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome
JAMA Neurol 75:353-359, Martinez-Ramirez, D.,et al, 2018
Atraumatic Lumbar Puncture Needles: Practice Needs to Change
Lancet 391:1128-1129, Van de Beek, D and Brouwer, M.C., 2018
Aminophylline for treatment of postdural puncture headache
Neurol 90:e1523-e1529, Wu, C.,et al, 2018
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
NEJM 378:1573-1582, Campbell, B.C.V.,et al, 2018
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
NEJM 378:1888-1897, Devinsky, O.,et al, 2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018
Effect of Treating Acute Optic Neuritis with Bioequivalent Oral vs Intravenous Corticosteroids
JAMA Neurol 75:690-696, Morrow, S.A.,et al, 2018
Beyond Large Vessel Occlusion Strokes
Stroke 49:1662-1668, Grossberg, J.A.,et al, 2018
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
NEJM 379:722-730,789, Tawbi, H.A.,et al, 2018
Interventions for Improving Modifiable Risk Factor Control in the Secondary Prevention of Stroke
Stroke 49:e301-e302, Bridgwood, B.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Efficacy of Botulinum Toxin A for Treating Cramps in Diabetic Neuropathy
Ann Neurol 84:682-690, Restivo, D.A.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Tocilizumab Treatment for New Onset Refractory Status Epilepticus
Ann Neurol 84:940-945, Jun, J.,et al, 2018
Endovascular Treatment for Patients with Acute Stroke Who Have a Large Ischemic Core and Large Mismatch Imaging Profile
JAMA Neurol 74:34-40, Rebello, L.C.,et al, 2017
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017